In continuation of my update on VIBERZI (eluxadoline)
Actavis announces FDA approval of VIBERZI (eluxadoline) for IBS-D treatment
Actavis plc, announced today that VIBERZI™ (eluxadoline) was approved by the Food and Drug Administration (FDA) as a twice-daily, oral treatment for adults suffering from irritable bowel syndrome with diarrhea (IBS-D). VIBERZI (eluxadoline) has mixed opioid receptor activity, it is a mu receptor agonist, a delta receptor antagonist, and a kappa receptor agonist.
"The FDA's approval of VIBERZI is the first step to providing physicians with a new, evidence-based, treatment option for their adult patients with IBS-D," said David Nicholson, Executive Vice President, Actavis Global Brands R&D. "At Actavis, we are dedicated to providing new treatment options, and the development of new agents that help address the most bothersome symptoms of IBS-D. We are very pleased to be working with the FDA to advance this IBS-D treatment and we eagerly await DEA scheduling determination later this year."
Ref : http://pubchem.ncbi.nlm.nih.gov/compound/11250029#section=Canonical-SMILES
Actavis announces FDA approval of VIBERZI (eluxadoline) for IBS-D treatment
